AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Sanofi

Report Publication Announcement Feb 23, 2024

1643_iss_2024-02-23_251d777a-b5fa-4372-90e6-36c2d051e752.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Press Release

Filing of the 2023 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report

Paris, February 23, 2024. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its "Document d'Enregistrement Universel" containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company's website: https://www.sanofi.com/en/investors/reports-and-publications/financial-reports-andregulated-information

In addition, the Form 20-F is available on the website of the SEC (www.sec.gov) and the "Document d'Enregistrement Universel" is available on the website of the AMF (www.amffrance.org). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Nicolas Obrist | + 33 6 77 21 27 55 | [email protected] Victor Rouault | + 33 6 70 93 71 40 | [email protected]

Investor Relations

Eva Schaefer-Jansen | + 33 7 86 80 56 39 | [email protected] Arnaud Delépine | + 33 6 73 69 36 93 | [email protected] Corentine Driancourt | + 33 6 40 56 92 21 | [email protected] Felix Lauscher | + 1 908 612 7239 | [email protected] Tarik Elgoutni | + 1 617 710 3587 | [email protected] Nathalie Pham | + 33 7 85 93 30 17 | [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.